目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T2328 | Bcr-Abl | ||
Radotinib (IY-5511) 有时被称为 IY5511,是一种用于治疗不同类型 Y 的药物,最显着的是费城染色体阳性 (Ph+) 慢性粒细胞白血病 (CML) 对其他酪氨酸激酶 Bcr-Abl 的耐药性或不耐受性抑制剂 | |||
T6079 | Apoptosis IGF-1R | ||
NVP-ADW742 (ADW) 是一种具有口服活性,选择性的IGF-1R 酪氨酸激酶抑制剂,IC50为 0.17 μM。它抑制胰岛素受体,IC50为 2.8 μM,在肿瘤细胞中诱导多效性抗增殖/促凋亡。 | |||
T3S1553 | COX Endogenous Metabolite | ||
trans-Cinnamaldehyde (Phenylacrolein) 是一种能够用于合成反式肉桂醛-β-环糊精复合物,一种能够食用的抗菌涂层,能够延长鲜切水果的保质期。它是一种能够通过烷基异氰化物与乙炔二羧酸二烷基酯的反应来合成高度多官能的呋喃环。 | |||
T10897 | Others | ||
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM against wild-type Bcr-Abl kinase and has anti-chronic myeloid leukemia (CML) activity. | |||
T12907 | Bcr-Abl PROTACs | ||
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM). | |||
T27555 | Others | ||
HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. | |||
T79081 | PROTACs | ||
ML 2-23是一种有效的PROTAC BCR-ABL降解剂,可在白血病细胞中通过蛋白酶体依赖的途径选择性地降解BCR-ABL。 | |||
T15056 | Akt | ||
DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM). | |||
T69045 | Others | ||
ON012380 is a non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I. | |||
T85318 | Others | ||
GMB-805 is a BCR-Abl PROTAC. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPY-04396 | C-ABL/ABL1 Protein, Human, Recombinant (GST) | Human | Baculovirus Insect Cells | ||
c-Abl belongs to the class of tyrosine kinases and is the prototype of a subfamily which includes two members, c-Abl and Arg (Abl-related gene). Both proteins are localized at the cell membrane, actin cytoskeleton and cytosol, and c-Abl is present in the nucleus as well. c-Abl is a non-receptor tyrosine kinase that participates in multiple signaling pathways linking the cell surface, cytoskeleton, and the nucleus. Recent in vitro studies have also linked c-Abl to amyloid-beta-induced toxicity and tau phosphorylation. c-Abl has been implicated in many cellular processes including differentiation, division, adhesion, death, and stress response. c-Abl is a latent tyrosine kinase that becomes activated in response to numerous extra- and intra-cellular stimuli. The c-Abl protein is a ubiquitously expressed nonreceptor tyrosine kinase involved in the development and function of many mammalian organ systems, including the immune system and bone. It regulates the cellular response to TAM through functional interaction with the estrogen receptor, which suggests c-Abl as a therapeutic target and a prognostic tumor marker for breast cancer. c-Abl also plays a key role in signaling chemokine-induced T-cell migration. In addition, c-Abl contains NLSs (nuclear localization signals) and DNA-binding sequences important for nuclear functions. c-Abl has become an important therapeutic target in human chronic myeloid leukaemia.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy
|
|||||
TMPY-00758 | Aminopeptidase N/CD13 Protein, Mouse, Recombinant (His) | Mouse | HEK293 Cells | ||
Aminopeptidase N/CD13 Protein, Mouse, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 104 kDa and the accession number is P97449.
|
|||||
TMPY-00665 | Aminopeptidase N/CD13 Protein, Human, Recombinant (I603M, His) | Human | HEK293 Cells | ||
Aminopeptidase N/CD13 Protein, Human, Recombinant (I603M, His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 104.2 kDa and the accession number is A0A024RC61.
|